WallStreetZenWallStreetZen

NASDAQ: AUTL
Autolus Therapeutics PLC Stock Forecast, Predictions & Price Target

Analyst price target for AUTL

Based on 1 analyst offering 12 month price targets for Autolus Therapeutics PLC.
Min Forecast
$9.00+107.37%
Avg Forecast
$9.00+107.37%
Max Forecast
$9.00+107.37%

Should I buy or sell AUTL stock?

Based on 1 analyst offering ratings for Autolus Therapeutics PLC.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AUTL stock forecasts and price targets.

AUTL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-03
lockedlocked$00.00+00.00%2023-12-13

1 of 1

Forecast return on equity

Is AUTL forecast to generate an efficient return?
Company
2.37%
Industry
76.1%
Market
79%
AUTL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AUTL forecast to generate an efficient return on assets?
Company
1.53%
Industry
30.96%
AUTL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AUTL earnings per share forecast

What is AUTL's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.78
Avg 2 year Forecast
-$0.62
Avg 3 year Forecast
-$0.26

AUTL revenue forecast

What is AUTL's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$22.7M+116.34%
Avg 2 year Forecast
$73.6M+600.95%
Avg 3 year Forecast
$205.8M+1,860.11%
AUTL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AUTL revenue growth forecast

How is AUTL forecast to perform vs Biotechnology companies and vs the US market?
Company
163.57%
Industry
35%
Market
9.85%
AUTL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AUTL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AUTL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AUTL$4.34$9.00+107.37%Buy
PRTA$21.48$67.83+215.80%Buy
CALT$38.90$39.25+0.90%Hold
DAWN$13.00$38.60+196.92%Strong Buy
DNA$0.51$1.70+234.65%Hold

Autolus Therapeutics Stock Forecast FAQ

Is Autolus Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: AUTL) stock is to Buy AUTL stock.

Out of 1 analyst, 0 (0%) are recommending AUTL as a Strong Buy, 1 (100%) are recommending AUTL as a Buy, 0 (0%) are recommending AUTL as a Hold, 0 (0%) are recommending AUTL as a Sell, and 0 (0%) are recommending AUTL as a Strong Sell.

If you're new to stock investing, here's how to buy Autolus Therapeutics stock.

What is AUTL's earnings growth forecast for 2024-2026?

(NASDAQ: AUTL) Autolus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.61%.

Autolus Therapeutics's earnings in 2024 is -$221,262,000.On average, 4 Wall Street analysts forecast AUTL's earnings for 2024 to be -$206,630,261, with the lowest AUTL earnings forecast at -$260,715,405, and the highest AUTL earnings forecast at -$133,018,064. On average, 4 Wall Street analysts forecast AUTL's earnings for 2025 to be -$164,144,291, with the lowest AUTL earnings forecast at -$218,149,625, and the highest AUTL earnings forecast at -$87,791,922.

In 2026, AUTL is forecast to generate -$68,743,735 in earnings, with the lowest earnings forecast at -$189,896,588 and the highest earnings forecast at $146,319,870.

What is AUTL's revenue growth forecast for 2024-2026?

(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 163.57% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.85%.

Autolus Therapeutics's revenue in 2024 is $10,497,000.On average, 4 Wall Street analysts forecast AUTL's revenue for 2024 to be $6,041,414,431, with the lowest AUTL revenue forecast at $2,721,549,589, and the highest AUTL revenue forecast at $15,224,715,533. On average, 4 Wall Street analysts forecast AUTL's revenue for 2025 to be $19,574,672,262, with the lowest AUTL revenue forecast at $12,732,489,086, and the highest AUTL revenue forecast at $29,130,956,016.

In 2026, AUTL is forecast to generate $54,737,731,444 in revenue, with the lowest revenue forecast at $36,611,891,935 and the highest revenue forecast at $95,078,651,786.

What is AUTL's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: AUTL) forecast ROA is 1.53%, which is lower than the forecast US Biotechnology industry average of 30.96%.

What is AUTL's Price Target?

According to 1 Wall Street analyst that have issued a 1 year AUTL price target, the average AUTL price target is $9.00, with the highest AUTL stock price forecast at $9.00 and the lowest AUTL stock price forecast at $9.00.

The Wall Street analyst predicted that Autolus Therapeutics's share price could reach $9.00 by Jun 3, 2025. The average Autolus Therapeutics stock price prediction forecasts a potential upside of 107.37% from the current AUTL share price of $4.34.

What is AUTL's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: AUTL) Autolus Therapeutics's current Earnings Per Share (EPS) is -$1.21. On average, analysts forecast that AUTL's EPS will be -$0.78 for 2024, with the lowest EPS forecast at -$0.98, and the highest EPS forecast at -$0.50. On average, analysts forecast that AUTL's EPS will be -$0.62 for 2025, with the lowest EPS forecast at -$0.82, and the highest EPS forecast at -$0.33. In 2026, AUTL's EPS is forecast to hit -$0.26 (min: -$0.71, max: $0.55).

What is AUTL's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: AUTL) forecast ROE is 2.37%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.